Newsroom
Sorted by: Latest
-
Nombre d’actions et droits de vote composant le capital social de Claranova SE au 30 septembre 2026
PARIS--(BUSINESS WIRE)--Regulatory News: Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement général de l’Autorité des Marchés Financiers, Claranova SE (Paris:ALCLA) (ISIN FR0013426004) publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 30 septembre 2026 : Actions composant le capital 57 206 910 Droits de vote théoriques (A) 57 206 910 Actions privées de droits de vote Autodétention au n...
-
Vertical Aerospace Receives Continued Listing Standard Notice from NYSE
NEW YORK & LONDON--(BUSINESS WIRE)--Vertical Aerospace (“Vertical” or the “Company”) [NYSE: EVTL], a global aerospace and technology company pioneering electric vertical take-off and landing (“eVTOL”) aircraft, today announced that it received a notice from the New York Stock Exchange (the “NYSE”) on September 9, 2026, indicating that the Company is not currently in compliance with the NYSE continued listing standard requiring a minimum average closing price for its ordinary shares of $1.00 over...
-
Bank of Marin Bancorp to Webcast Q3 Earnings on Monday, October 26, 2026, at 8:30 a.m. PT
NOVATO, Calif.--(BUSINESS WIRE)--Bank of Marin Bancorp to Webcast Q3 Earnings on
Monday, October 26, 2026, at 8:30 a.m. PT...
-
Pershing Square Declares Fourth Quarter 2026 Dividend
NEW YORK--(BUSINESS WIRE)--Pershing Square Inc. (NYSE:PS) (“Pershing Square” or the “Company”) today announced that its Board of Directors (the “Board”) has declared a quarterly cash dividend of $0.103 per share of its common stock for the fourth quarter of 2026, payable on October 20, 2026 to shareholders of record as of the close of business on October 12, 2026. The declaration and amount of any future quarterly cash dividends are at the sole discretion of the Board and may be variable from q...
-
KBRA Assigns AA+ Rating, Stable Outlook to the City of New York General Obligation Bonds
NEW YORK--(BUSINESS WIRE)--KBRA assigns a long-term rating of AA+ with a Stable Outlook to the following City of New York General Obligation Bonds (the Bonds): Fiscal 2027 Series D (Tax-Exempt) Fiscal 2027 Series E consisting of Subseries E-1 (Tax-Exempt) and Subseries E-2 (Taxable) Fiscal 2027 Series F (Tax-Exempt) Fiscal 2027 Series G (Taxable) Proceeds of the Fiscal 2027 Series D (Tax-Exempt) Bonds will be used for capital purposes. Proceeds of the Fiscal 2027 Subseries E-1 (Tax-Exempt) Bond...
-
Moody’s AnalyticsوAllvue تطلقان نموذجًا لمخاطر الائتمان لتحديد المؤشرات المبكرة لضغوط المقترضين في مجال الائتمان الخاص
نيويورك--(BUSINESS WIRE)--اليوم، أعلنت كل من Moody’s Corporation (رمزها في بورصة نيويورك: MCO) وهي الشركة الرائدة عالميًا في تقييم المخاطر وتحليلات الائتمان، وشركة Allvue Systems، الرائدة في مجال التكنولوجيا والبيانات لأسواق رأس المال الخاصة، عن إطلاق نموذج Moody's Analytics EDF-X Private Credit Model، وهو نموذج جديد لمخاطر الائتمان مصمم خصوصًا لسوق الائتمان الخاص. ويعتمد النموذج على خبرة Moody’s العميقة في مجال الائتمان بالإضافة إلى بيانات أداء الائتمان الخاص لدى شركة Allvue، ويحدد الإشارات ا...
-
Deadline Approaching: Qfin Holdings, Inc. (QFIN) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming November 30, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Qfin Holdings, Inc. (“Qfin” or the “Company”) (NASDAQ: QFIN) securities between March 18, 2026 and August 25, 2026, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN QFIN HOLDINGS, INC. (QFIN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONG...
-
Celanese to Hold Third Quarter Earnings Conference Call on November 3, 2026
DALLAS--(BUSINESS WIRE)--Celanese to Hold Third Quarter Earnings Conference Call on November 3, 2026...
-
ILiAD Biotechnologies amplía el potencial comercial y de salud pública de BPZE1 con la publicación de un estudio pediátrico de fase 2b en *The Lancet Infectious Diseases*
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), una empresa de biotecnología en etapa clínica avanzada enfocada en la prevención y el tratamiento de enfermedades causadas por Bordetella pertussis, anunció el día de hoy la publicación de los resultados de su ensayo clínico de Fase 2b SUPER (Stand Up to Pertussis) en la revista The Lancet Infectious Diseases. Este ensayo aleatorizado, doble ciego y controlado con placebo y comparador activo demostró que BPZE1, una vacuna intra...
-
Arcosa, Inc. Announces Commencement of Bondholder Calls
DALLAS--(BUSINESS WIRE)--Arcosa, Inc. (NYSE: ACA) (“Arcosa” or the “Company”), a provider of infrastructure-related products and solutions, today announced it will hold quarterly bondholder calls for the benefit of the holders of the Notes, the Trustee, beneficial owners of the Notes, prospective purchasers of the Notes, securities analysts and market making financial institutions to ask questions following the release of its quarterly financial information, beginning with the Quarterly Report...